comparemela.com

Latest Breaking News On - Leica bond - Page 1 : comparemela.com

Overexpression of Nfe2l1 increases proteasome activity and delays vision loss in a preclinical model of human blindness

Overexpression of Nfe2l1 increases proteasome activity and delays vision loss in a preclinical model of human blindness
science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.

United-states
Japan
Wetzlar
Hessen
Germany
Cyagen-santa-clara
Leica-microsystems-gmb
Bioresource-research-center-kyoto
Biotechnology-research
Uf-interdisciplinary-center
Microsoft
Jackson-laboratory

Analyzing regulatory and effector T cells in tumors

In this interview, Cerba Research describes how its teams were able to detect resident memory T cells in solid tumors thanks to multiplex immunofluorescence.

Louis-castel
Cerba-researchmar
Histalim-histoprofile
Akoya-biosciences
Polaristm-akoya-biosciences
Leica
Cerba-research
Sponsored-content
Patient-derived-xenograft
Leica-bond
Image-credit
Cancer

Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML) | Journal of Translational Medicine

The survival rate for patients with relapsed and refractory acute myeloid leukaemia (R/R-AML) remains poor, and treatment is challenging. Chimeric antigen receptor T cells (CAR-T cells) have been widely used for haematologic malignancies. Current CAR-T therapies for acute myeloid leukaemia mostly target myeloid-lineage antigens, such as CD123 and CD33, which may be associated with potential haematopoietic toxicity. As a lineage-specific receptor, CD7 is expressed in acute myeloid leukaemia cells and T cells but is not expressed in myeloid cells. Therefore, the use of CD7 CAR-T cells for R/R-AML needs to be further explored. In this report, immunohistochemistry and flow cytometry were used to analyse CD7 expression in clinical samples from R/R-AML patients and healthy donors (HDs). We designed naturally selected CD7 CAR-T cells to analyse various functions and in vitro antileukaemic efficacy based on flow cytometry, and xenograft models were used to validate in vivo tumour dynamics. We

China
Germany
Beijing
Japan
United-states
Israel
Hebei
Jilin
Miltenyi-biotec
Texmacs-miltenyi-biotec
Dynabeads-gibco
Macsquant-miltenyi-biotec

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.